Cyclic Polypeptide C5 Inhibitors for Specific Complement Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-related disorders, such as paroxysmal nocturnal hemoglobinuria, autoimmune diseases, and neurological diseases, face challenges in selectively inhibiting complement-mediated cell destruction without causing harm to self-cells, as existing therapies lack specificity and potency.
Innovation Solution
Development of novel polypeptides, including cyclic polypeptides and peptidomimetics, that inhibit complement component C5 activity by binding to specific regions on C5, preventing its cleavage into C5a and C5b, thereby reducing membrane attack complex formation and inflammation, with IC50 values ranging from 50 nM to 200 nM.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to inhibit complement activity, then complement-mediated cell destruction is reduced, but specificity and potency are insufficient causing harm to self-cells
Solution Approach 1:
The patent applies local quality by designing polypeptides with specific structural features (cyclic structures, disulfide bridges, particular amino acid sequences) that enable selective binding to C5 at specific locations. This localized structural optimization allows the inhibitor to target only the complement pathway without affecting other physiological processes, thereby achieving high specificity while preventing harm to self-cells
Solution Approach 2:
The patent utilizes parameter changes by optimizing the IC50 values of the polypeptides to fall within a specific range (50-200 nM), which represents a significant improvement over existing therapies. This quantitative parameter optimization ensures potent inhibition of C5 cleavage while maintaining safety margins that prevent off-target effects on self-cells
2Reliability
If existing therapies are used to inhibit complement activity, then complement-mediated cell destruction is reduced, but potency is insufficient requiring higher doses
Solution Approach 1:
The patent achieves improved potency by optimizing the IC50 parameter to 50-200 nM, which is significantly lower than existing therapies. This parameter optimization means that effective inhibition of C5 occurs at lower concentrations, directly reducing the quantity of substance required while enhancing the therapeutic effect
3Reliability
If polypeptides are designed to bind specifically to C5, then C5 cleavage is inhibited, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the polypeptide structure into distinct functional domains: N-terminal region, C-terminal region, disulfide bridge formation, and cyclic structure elements. This modular segmentation allows each component to contribute specifically to binding affinity and specificity while maintaining overall structural manageability and enabling rational design approaches
Solution Approach 2:
The patent employs composite material principles by combining multiple structural features (cyclic peptides, disulfide bridges, specific amino acid sequences, secondary structures) into a unified polypeptide architecture. This composite design achieves high binding specificity to C5 while the synergistic interaction of various structural elements compensates for the increased complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polypeptides effectively inhibit C5 cleavage and MAC formation, offering a potent and specific therapeutic approach for treating complement-related diseases by reducing cell lysis and inflammation, with potential applications in conditions like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Implementation Method 1
Activation occurs by way of a pathway of proteolytic cleavage initiated by pathogen recognition and leading to pathogen destruction
Implementation Method 2
Three such pathways are known in the complement system and are referred to as the classical pathway, the lectin pathway and the alternative pathway
Data Source
AI summary
The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.